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Early Diagnosis of Abdominal cancer in General Practice
Early diagnosis of abdominal cancer in general practice 
1. Relevance
Cancer is a leading cause of death. The number of new cases is increasing every year. The 
reasons for this are complex and in part due to an ageing population, but cancer affects all age 
groups. The general practitioner (GP) participates actively in the diagnosis of cancer (1;2)  
and is directly involved in the initial diagnosis of more than 80% of all cancer cases with 
some variation for different forms of cancer (3). GPs must confront the professional challenge 
that among many patients with possible cancer symptoms, only a handful actually has cancer. 
Published studies show that cancer is an area where the GP needs all his or her clinical 
competence (4;5). Early diagnosis is generally considered decisive for a good prognosis. 
Research is needed to clarify how the GP can work more efficiently towards early clinical 
diagnosis of cancer (6). 
The relationship between abdominal symptoms and cancer needs to be clarified and 
will be studied in the present cohort study. Our research takes place in general practice 
surgeries and is based on real patients, with six months prospective recording of new cases of 
cancer and data related to these patients. Such research could contribute to improving cancer 
diagnostic work in general practice (7). Our research for the first time will try to benefit from 
collaboration in the CA-PRI  network (The Cancer and Primary Care  Research International 
Network) (http://www.ca-pri.com/ ) created in 2008, that aims to promote international 
research collaboration about cancer in primary care. The project leader is member of the 
Executive group of CA-PRI and was invited key-note speaker when the network was 
established.   
2. Aspects relating to the research project
The main objectives (also described in the grant application form) are: 
Primary objective: 
To investigate the importance and impact of symptoms, findings, supplementary 
investigation, co-morbidity and the GP’s degree of suspicion of cancer in abdominal cancer 
diagnosis in primary care.  
Secondary objectives are to establish: 
-Validity figures (sensitivity, specificity and likelihood ratio) of recorded symptoms and of 
combined focal and general symptoms in relation to abdominal cancer generally, and in 
relation to major forms of abdominal cancer, like colorectal cancer and ovarial cancer.  
-Predictive value of symptoms in the total patient population and in national patient 
populations.  
-Correlations between symptoms on the one hand and supplementary tests, imaging, referral 
and follow-up in the GP’s own surgery on the other 
-Symptom differences between the sexes in forms of cancer affecting both sexes, and between 
age groups 
-Good diagnostic strategies for the GP towards the recognition of different forms of  
abdominal cancer 
2.1. Background and status of knowledge 
2.1.1. Clinical studies about cancer are mostly performed in hospitals. Many studies are 
relevant for general practice, but clinical realities differ between general practice and 
hospitals, and research based diagnostic strategies also need data from patients consulting in 
general practice.  
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 Our research project builds on experience from previous studies on early diagnosis of 
cancer (8;8;8;9) and is part of an ongoing greater “umbrella” project about cancer care in 
general practice (10;11). In this greater project, data about possible cancer symptoms for all 
sorts of cancer, collected in general practice, and questionnaire and interview data about how 
the GP is involved in diagnosis and treatment of cancer, are about to be analysed. One PhD 
student recently submitted a first article. From the data already collected we have seen that 
more detailed data are needed about the important group of cancer forms located in the 
abdomen, and about abdominal symptoms and cancer in general. 
 Interesting studies about the relationship between symptoms and cancer have been 
performed in primary care with different methodologic approaches; cohort study  (4),  
qualitative (12) or case control (13) design. Some studies have made systematic reviews of 
published studies of symptoms like haematuria (14) or of diagnostic delay (15). Reducing 
unnecessary delay is both of psychological and prognostic importance in many cases (5;16). 
A strategy like “fast track” referrals for suspected cancer has not yet improved outcomes in 
the UK (17) but is receiving attention in Denmark (18). “Alarm symptoms” increase the risk 
of cancer, but the diagnosis is still rare (19).  
 Among abdominal cancers, colorectal cancer is the most common form, while ovarian 
cancer has received attention because of its reputation as a “silent killer” (20) . For colorectal 
cancer, a British study has investigated pathways to the diagnosis (21) and prospective risk 
after rectal bleeding (22). Most alarm features have poor sensitivity and specificity for 
colorectal cancer (23), but maximizing sensitivity of tests may improve diagnostic strategies 
in primary care (24;25). A potential for cutting mortality through improved practice in 
primary care seems to exist (26). For ovarian cancer, studies with varied methodology (27;27-
29)  have shown that this cancer may be less “silent” than was previously thought. However, 
identifying potential patients in primary care remains difficult (30;31) because predictive 
value of single symptoms will remain low in a large primary care patient population. This is 
also so for urological cancer becoming manifest through haematuria (32) (14) . Prostate 
cancer in locally advanced stage have clinical features similar to benign prostate hypertrophy. 
The clinical challenges of this has been studied by Hamilton et al (33;34), but wise primary 
care diagnostic strategies are not clear. For other and more rare forms of abdominal cancer 
data from primary care are scarce, and even studies from hospitals and epidemiological cancer 
registers will often be based on case-control design of certain but limited value. Studies in 
primary care require multi-practice collaboration, and symptoms in actual patients will often 
be the natural starting point rather than the disease. 
 
2.2. Approaches, hypotheses and choice of method 
2.2.1. Method and material 
We want to do a cohort study including approximately 110-120 000 consecutively consulting 
patients in general practice. Through international collaboration around 600 GPs will be 
recruited to register all patients consulting during ten workdays within a period of one month. 
Earlier studies have shown some symptoms to be valid but unspecific in relation to different 
forms of cancer.  
Our primary care collaborative study is expected to give rather  detailed information 
and expand current knowledge about how GPs can deal with symptoms in consultations with 
individual patients. Such knowledge is an important prerequisite for GP work toward earlier 
diagnoses of cancer. For example, while single “alarm” symptoms have been studied to some 
extent (but hardly enough) in primary care, studies focusing on general symptoms or the 
combination of symptoms are rare (35) . Also, the focus on symptoms presented is a realistic 
clinical starting point in general practice and may give information not covered by 
epidemiological or hospital based research. Our design permits analysis both from starting 
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point “symptom” and also from starting point “specific cancer disease”. We hypothesize that 
the study can identify combinations of symptoms that have higher predictive value than single 
symptoms, and that we may find differences between the sexes in symptom presentations of 
the same kind of cancer.  
We choose a patient-near design that is not possible in the many studies based on 
patient registers. The prospective cohort and patient-near design is rare in clinical studies in 
primary care. The cohort design combines prospective follow-up with retrospective analysis 
and is less sensitive to recall bias than the more common case-control studies. For practical 
procedures, see 3.2.1     
2.2.2. Power calculations 
Cancer incidence in Norway 2008 was 0,55%, and for abdominal forms of cancer 
approximately 0,27% (36). Sick persons consult more than the average population, and in our 
previous study the number of cancers recorded were higher than expected from incidence 
figures. In this yet unpublished study we found 350 new cases of cancer in 65 000 patients, or 
0,54% over the 10 day period, collected by 330 GPs, i.e. slightly more than one cancer case 
per GP. This corresponds to each GP diagnosing 15-20 cases of cancer every year, 
considering that some working days are spent outside the surgery in mother and child clinics, 
old people’s homes, etc..The number is higher that the commonly quoted figure of six to ten 
new cases of cancer yearly in a GP’s surgery, and it is possible that we should expect the 
number of cancer cases in our study to be lower then one case per GP. In Norway, 49.3% or 
approximately half of cancer cases are abdominal forms of cancer. Colorectal cancers make 
up 13,0% of all cancers, and ovarial cancers 1,7% (36) 
Like Hamilton et al. (37) we base our power calculations on the symptom of 
abdominal pain. In Norwegian general practice, 1,8% of consulting patients in the year 2000 
had an ICPC diagnosis of abdominal pain. The true percentage must be a little higher, because 
abdominal pain may not have been recorded as the main diagnosis. In a British study (38) , 
10% of the adult consulting population had abdominal pain. We choose an expected 
frequency of abdominal pain to be between these two figures; i.e. 5%, for use in calculations. 
In the British study (38) 42,4% of colorectal cancer patients presented abdominal pain. 
We expect 40% of patients with any kind of abdominal cancer to present abdominal pain 
before diagnosis. This is compared with 5% of patients without abdominal cancer. We then 
get two proportions: P1=0,0222 (number of patients with abdominal cancer and abdominal 
pain divided with the number of all patients with abdominal pain) and P2=0,0018 (number of 
patients with abdominal cancer and without abdominal pain divided with the number of all 
patients with abdominal pain). We choose a statistical significance level of 0.05 and power of 
0.9. Based on power calculations for compared proportions (two-sided Z test with unpooled 
variance) we then need to include 10 960 patients to show whether abdominal pain is a valid, 
discriminating symptom in relation to abdominal cancer.  
We also made a calculation based on a scenario with less difference in the frequency 
of abdominal pain in patients with and without abdominal cancer. The highest incidence of 
abdominal pain we found registered in consulting patients in general practice was 10% (38). 
In a case-control study of ovarian cancer abdominal pain occurred in 55% of the patients but 
in only 18 % of stage I patients, and “pain in side of trunk and flank” occurred in only 19% 
(39). Using these “worst case scenario” proportions  of 10% and 19% (P1=0,0053 and 
P2=0,0025) we need to include 72 760 patients.  
Each GP will record a maximum of 20 patients for 10 days or 200 patients. With 
international collaboration we this time want to have around 600 GPs record data about their 
patients, thereby expecting data about approximately 110-120 000 patients. With one new 
case of abdominal cancer for every second GP this will include data about 300 abdominal 
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cancer patients and a similar number of patients with other forms of cancer, or perhaps 250 
cases of abdominal cancer if we get less than one cancer case per GP. With this size of the 
cohort, the expected number of patients with and without cancer could be high enough to 
calculate validity data for some less frequent single symptoms and for combinations of 




Analysis of sensitivity, specificity and likelihood ratio of recorded symptoms and 
combination of symptoms. It will be interesting to combine focal and general symptoms and 
see which combinations seem to have greatest importance for a diagnostic strategy. Predictive 
value of symptoms in the total  GP population and in national GP populations can be 
calculated. The value of a GP hunch for cancer will be suggested, as well as the value of 
supplementary examinations and referrals. Data will also show which of the listed symptoms 
are correlated to GPs’ ordering of supplementary tests or referrals, or follow-up consultations 
in the GP’s own practice. We want to analyze differences between males and females to look 
for effects similar to what has been shown for coronary disease (40), that symptoms may 
differ between the sexes. A similar analysis may compare older and younger patients.   
 
2.2.4. Pilot study 
A pilot study has been performed by the principal investigator and should be performed by 
national coordinators in each country before start. The time zero form is simple to complete. 
If completed after each patient, it normally takes less than one minute per patient. It is also 
possible to complete one form at the end of each working day. The form used six months later 
will be completed by each GP for only one or two patients in most cases and is also relatively 
short and simple to complete. It is a modified and shortened version of a form used in 
previous studies of cancer patients in primary care (2) 
 
 
2.3. The project plan, project management, organisation and cooperation  
The project period and project plan encompassing the project’s main activities and milestones 
are provided in the grant application form. 
 
2.3.1. Project plan 
At time zero 
A simple and well-known audit form, developed especially for registrations in general 
practice, is used (Appendix 1). In this form, anonymous registration of symptoms and other 
variables in consecutively consulting patients in general practice will be done. For 10 working 
days within a period of one month each GP should complete one form per day with space for 
recording a maximum of 20 patients each day. All patients (however max 20) consulting 
during one of the ten days, with and without abdominal symptoms and regardless of the 
purpose of their visit, should be recorded, as a minimum with sex and date of birth. For 
patients presenting abdominal symptoms, additional data should be recorded. This has been 
tested and will take about one minute per symptomatic patient. 
The variables deal with symptom(s), duration of symptoms, whether the consultation 
is a first or a subsequent visit to the GP for the presented problem, findings from different 
organ systems, supplementary blood tests, imaging, referrals, follow-up in general practice,, , 





After six months 
Anonymized data about patients diagnosed with a cancer during the period between the initial 
registration and six months later will be asked for from each participating GP. These 
individual patient data are recorded on a 5-page simple questionnaire (Appendix 2). The GP 
must find this information in electronic patient records from the days of initial recording. 
Records for all (ideally 20 patients x 10 days = 200) patients must be reviewed regardless of 
whether they presented symptoms or not. This will take about one hour for each GP. The 
interval of six months has been chosen because a cancer present during the initial consultation 
will usually have become manifest and diagnosed six months later. For example, in an 
interview study with women with ovarian cancer, most women said their symptoms started 
about five months before their cancer was diagnosed (Mayor 2009 again). The interval is also 
short enough to increase the probability that a recorded symptom has something to do with the 
yet undiagnosed cancer. Each GP can be expected to find zero to two cancer patients 
stemming from the ten-day registration period, and half of these cancers will be abdominal 
forms of cancer. Completing one cancer patient form will take about fifteen minutes. Patients 
with non-abdominal cancers will also be recorded.  
If a GP has more than 20 consulting patients in the surgery on one day and thus does 
not register the last consulting patients on that day, then it is not expected that such patients 
are reported on the six month form, even if cancer has been diagnosed. Such omissions are 
expected to be rare and haphazard and should not distort analysis. Telephone consultations 
and mere renewal of prescriptions should not be counted as consultations.  
2.3.2. Organisation 
The project base with the project leader, project partner, project coordinator, PhD student and 
project technician will be at the Institute of Community Medicine, University of Tromsø, 
Norway. The University of Tromsø also provides support through the permanent technical 
and administrative staff. Our Institute has an active teaching environment and offers PhD 
teaching courses. A number of PhD students work at the Institute.  
The project leader is Professor Dr. Med. Knut Holtedahl whose main research interest 
is early diagnosis of cancer and who is head of the General Practice section of the Institute of 
Community Medicine.  
Project partner is professor II at the University of Tromsø Anna Luise Kirkengen. She 
is an experienced researcher with broad theoretical orientation and long clinical practice. 
The project group in Tromsø has prepared the protocol and the forms to be sent to the 
GPs at time zero and after 6 months. International collaboration is established. Informal 
contacts at the latest CA-PRI meeting in spring 2009 showed considerable interest in 
recruitment of GPs from other delegates and written expressions of collaboration interest has 
been collected from five countries (the Belgian/Dutch team is counted as one). Norwegian 
GPs will be recruited from the project base in Tromsø. 
All forms and guidelines will be printed in Norway and distributed from The 
University of Tromsø to the international collaborators. We plan to furnish pre-packed and 
pre-addressed envelopes to GPs in the collaborating countries, and pre-addressed return 
envelopes. When completed, forms will be collected by the international collaborators and 
then sent to The University of Tromsø where data registration and analysis will be carried out 
and articles written for international publication.  
International collaboration:  
Through the international CA-PRI network we have invited selected researchers with 
experience in cancer research in primary care to be international partners. Researchers from 
several countries have been invited to be international partners and act as national 
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coordinators and co-researchers. At present, the following partners have returned signed 
expressions of interest: 
1. Professor Eva Grunfeld, University of Toronto, Canada. Experienced researcher with
follow-up of cancer patients in primary care as her main research interest.  
2. Professor Jon Emery, University of Western Australia. Chair of the Cancer Australia
Primary Care Collaborative Cancer Clinical Trials Group.  
3. Professor Frank Buntinx, Leuven University, Belgium, together with Profesor Geert Jan
Dinant, Maastricht University, the Netherlands, to form one Belgian-Dutch collaboration 
group. Prof. Buntinx has a major research interest in early diagnosis of urinary cancer in 
primary care, and prof. Dinant has broad primary care research interests, among them the 
question of “gut feeling” in early diagnosis. He already has another research cooperation with 
the Primary Care unit at the University of Tromsø.   
4. Clinical lecturer Elizabeth Delaney, University of Aberdeen, Scotland. Research interests in
early diagnosis of cancer, especially skin cancer and ovarian cancer. Professor David Weller, 
Edinburgh, who is co-founder of the CA-PRI network, has suggested that he will support Dr. 
Delaney’s work with the study in Scotland.  
5. Professor Lars Borgström, University of Linköping, Sweden. Head of Department of
Family Medicine. Experienced researcher with broad interests within family medicine and 
health services research.  
Their acceptances are enclosed in the grant application form.  
In Mai 2010 in Toronto, Canada, there will be a CA-PRI meeting where our project 
will be presented. During the CA-PRI meeting the project leader and the project coordinator 
will meet with the international collaborators to discuss the project and get scientific input 
from the partners and to finalise and agree on the practical planning. The international 
partners are expected to contribute to the project with their scientific knowledge and 
experience. This already began when the draft of the project was presented on the 2009 CA-
PRI meeting. The international partners will be offered co-authorship according to the 
Vancouver editorial rules, where it is expected that they also participate with comments and 
ideas during the writing of articles. After international publication, international partners will 
be free to analyse and publish separately their national data.  
 Furthermore they are expected to: 
- Help translate the forms, letters and guidelines to the GPs into the language they use in their 
country, if it is not English or Norwegian.  
- Address GP colleagues that could be recruited as collaborators and try to obtain their 
consent.  
- Act as a local coordinator and be prepared to serve as a contact person and answer questions 
from participating GPs on mail. The project staff in The University of Tromsø will be happy 
to assist if difficult questions are asked. 
-Collect pre-addressed, pre-stamped return envelopes with completed forms from each GP. 
Once or twice a month the coordinator should forward the envelopes to The University of 
Tromsø. 
Concerning plans for an overseas fellowship, the Danish research centre for  cancer 
diagnosis in primary care is located at the Research Unit for General Practice at Aarhus 
University, where there is an active research environment and where a number of PhD 
degrees have been produced in later years. 
2.3.3. Data handling 
A program for electronic reading of the forms has been made and has been used in a previous 
study. The completed forms should be returned to the national coordinator in each country in 
a pre-addressed and pre-stamped envelope, and the forms will be forwarded to the University 
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of Tromsø for electronic treatment with manual surveillance. Only the individual GP will 
know the identity of any single patient.  
Quantitative data will be recorded and analyzed in SPSS. 
 
2.3.4 Time plan 
The project period and progress plan encompassing the project’s main activities and 
milestones are also provided in the grant application form.  
 
2010: Discussions and meeting with international collaborators. Protocol completed. 
Questionnaires finalized and made ready for distribution.. 
2011: Data collection. Plans for an overseas research stay at the recently established Danish 
research centre for  cancer diagnosis in primary care in Aarhus, Denmark 
2012 : Analysis and beginning of article writing. Three clinical epidemiological articles about 
the relationship between collected variables and cancer are planned.  
2013: Presentations at international and national congresses. Article writing continues.  
2014: Concluding work. 
 
2.4. Budget 
Budget information is included in the grant application form.  
 
3.  Perspectives and compliance with strategic documents  
3.1. Compliance with strategic documents 
The project repesents patient-near research, which complies with the goal that the Norwegian 
Research Council has set for the announced grant. Cancer research in primary care could 
comply with ideals about better coordination of health services, expressed in the Health 
Ministry’s recent Coordination reform document from 2009. The Research strategy document 
from the Health Department for 2006-11 defines “Practice-near” research in primary care as 
very important. The project is also in concordance with a research strategic document from 
the General Practice Association (within the Norwegian Medical Asociation) from 2005. 
Finally, the Institute of Community Medicine at the University of Tromsø has got research in 
general practice as one of its three main research strategic interests.   
 
3.2. Relevance to society 
Mortality from cancer has declined in later years. Contributing to further decline is considered 
one of the main goals of public health in all countries.  
 
3.3. Environmental perspectives 
Not relevant in this project 
 
3.4. Ethical aspects 
The already completed cancer project with similar design had clearing from the Regional 
Medical Ethics Committee and permission from the Data Surveillance Authority in Norway. 
All necessary permissions will be applied for in the present project. The researchers will not 
know other personal patient data than sex and date of birth, and where the patient’s GP works.  
 
3.5. Gender equality and gender perspectives  
The recruitment of consecutively consulting patients in general practice will assure 
participation of both genders in the study. Cancer affects both sexes, and we will look for sex 




4. Communication with users and utilisation of results
4.1 Communication with users 
National coordinators will communicate by mail, on telephone and through yearly meetings at 
the CA-PRI conferences. Each national project coordinator is expected to have close 
communication with participating GPs and be available on the phone around the time of 
registrations. Publications and a certificate of participation will be sent to all participating GPs 
who want this (a question about this has been included in the six months form).  
4.2. Dissemination plan 
Publication in international medical journals, presentations in international and national 
conferences.   
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